Methodological quality and synthesis of case series and case reports

Mohammad Hassan Murad,1 Shahnaz Sultan,2 Samir Haffar,3 Fateh Bazerbachi4

Abstract

Case reports and case series are uncontrolled study designs known for increased risk of bias but have profoundly influenced the medical literature and continue to advance our knowledge. In this guide, we present a framework for appraisal, synthesis and application of evidence derived from case reports and case series. We propose a tool to evaluate the methodological quality of case reports and case series based on the domains of selection, ascertainment, causality and reporting and provide signalling questions to aid evidence-based practitioners and systematic reviewers in their assessment. We suggest using evidence derived from case reports and case series to inform decision-making when no other higher level of evidence is available.

In 1904, Dr James Herrick evaluated a 20-year-old patient from Grenada who was studying in Chicago and suffered from anaemia and a multi-system illness. The patient was found to have ‘freakish’ elongated red cells that resembled a crescent or a sickle. Dr Herrick concluded that the red cells were not artefacts because the appearance of the cells was maintained regardless of how the smear slide was prepared. He followed the patient who had subsequently received care from other physicians until 1907 and questioned whether this was syphilis or a parasite from the tropics. Then in 1910, in a published case report, he concluded that this presentation strongly suggested a previously unrecognised change in the composition of the corpuscle itself.1 Sickle cell disease became a diagnosis thereafter.

Case reports and case series have profoundly influenced the medical literature and continue to advance our knowledge in the present time. In 1985, the American Medical Association reprinted 51 papers from its journal that had significantly changed the science and practice of medicine over the past 150 years, and five of these papers were case reports.5 However, concerns about weak inferences and the high likelihood of bias associated with such reports have resulted in minimal attention being devoted to developing frameworks for approaching, appraising, synthesising and applying evidence derived from case reports/series. Nevertheless, such observations remain the bread and butter of learning by pattern recognition and integral to advancing medical knowledge.

Guidance on how to write a case report is available (ie, a reporting guideline). The Case Report (CARE) guidelines3 were developed following a three-phase consensus process and provide a 13-item checklist that can assist researchers in publishing complete and meaningful exposition of medical information. This checklist encourages the explicit presentation of patient information, clinical findings, timeline, diagnostic assessment, therapeutic interventions, follow-up and outcomes.7 Yet, systematic reviewers appraising the evidence for decision-makers require tools to assess the methodological quality (risk of bias assessment) of this evidence.

In this guide, we present a framework to evaluate the methodological quality of case reports/series and synthesise their results, which is particularly important when conducting a systematic review of a body of evidence that consists primarily of uncontrolled clinical observations.

Definitions

In the biomedical published literature, a case report is the description of the clinical course of one individual, which may include particular exposures, symptoms, signs, interventions or outcomes. A case report is the smallest publishable unit in the literature, whereas case series report aggregates individual cases in one publication.4

The median number of patients in articles with ‘case series’ in the title was found to be seven (range 1–6432). The median (range) of the number of cases of articles with ‘case report’ as a publication type was four (1–178).5 Case reports/case series are usually retrospective although can occasionally be prospective, such as the Herrick’s first case report of sickle cell disease.1 Case reports/series can also define their subject by exposure or outcome (analogous to a cohort study and case–control study). Therefore, a specific number of patients, the temporal direction of follow-up or even the definition by case/exposure are not differentiating characteristics of case report/series. One unique feature, however, is that case report/series are uncontrolled (non-comparative) and have a relatively small number of individuals.

If a case series is prospective, differentiating it from a single-arm uncontrolled cohort study becomes difficult. In one clinical practice guideline, it was proposed that studies without internal comparisons can be labelled as case series unless they explicitly report having a protocol before commencement of data collection, a definition of inclusion and exclusion criteria, a standardised follow-up and clear reporting of the number of excluded patients and those lost to follow-up.6

1Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA 2Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Center for Chronic Diseases Outcomes Research, Minneapolis Veterans Affairs Healthcare System, Minneapolis, Minnesota, USA 3Digestive Center for Diagnosis and Treatment, Damascus, Syrian Arab Republic 4Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA

Correspondence to: Dr Mohammad Hassan Murad, Evidence-Based Practice Center, Mayo Clinic, Rochester, MN 55905, USA; murad.mohammad@mayo.edu

References

1Herrick J. A case of irregular red cells. JAMA 1904;42:836–42.
2Herrick J. A case of irregular red cells. JAMA 1907;47:1512–7.
3Murad MH, Sultan S, Haffar S, et al. BMJ Evidence-Based Medicine 2018;23:60–63.

To cite: Murad MH, Sultan S, Haffar S, et al. BMJ Evidence-Based Medicine 2018;23:60–63.
Evaluating methodological quality

Pierson1 provided an approach to evaluate the validity of a case report based on five components: documentation, uniqueness, objectivity, interpretation and educational value, resulting in a score with a maximum of 10 (a score above 5 was suggested indicative of a valid case report). This approach, however, was rarely used in subsequent work and seems to confute methodological quality with other constructs. For case reports of adverse drug reactions, other systems classify an association as definite, probable, possible or doubtful based on leading questions.9–9 These questions are derived from the causality criteria that was established in 1965 by the English epidemiologist Bradford Hills.10 Lastly, we have adapted the Newcastle Ottawa scale11 for cohort and case–control studies by removing items that relate to comparability and adjustment (which are not relevant to non-comparative studies) and retained items that focused on selection, representativeness of cases and ascertainment of outcomes and exposure. This tool was applied in several published systematic reviews with good inter-rater agreement.12–16

Proposed tool

The previous criteria from Pierson,7 Bradford Hills10 and Newcastle Ottawa scale modifications11 converge into eight items that can be categorised into four domains: selection, ascertainment, causality and reporting. The eight items with leading explanatory questions are summarised in table 1.

For example, a study that explicitly describes all the cases who have presented to a medical centre over a certain period of time would satisfy the selection domain. In contrast, a study that reports on several individuals with unclear selection approach leaves the reader with uncertainty to whether this is the whole experience of the researchers and suggests possible selection bias. For the domain of ascertainment, self-report (of the exposure or the outcome) is less reliable than ascertainment using administrative and billing codes, which in turn is less reliable than clinical records. For the domain of causality, we would have stronger inference in a case report of an adverse drug reaction that has resolved with cessation of the drug and reoccurred after re-introduction of the drug. Lastly, for the domain of reporting, a case report that is described with sufficient details may allow readers to apply the evidence derived from the report in their practice. On the other hand, an inadequately reported case will likely be unhelpful in the course of clinical care.

We suggest using this tool in systematic reviews of case reports/series. One option to summarise the results of this tool is to sum the scores of the eight binary responses into an aggregate analysis to demonstrate that both QT interval and left ventricular ejection fraction were significantly correlated with corrected total serum calcium level.12 Meta-regression, which is a regression appropriate when one or two questions are deemed most critical to the validity of a report (compared with other questions). Therefore, we suggest making an overall judgement about methodological quality based on the questions deemed most critical in the specific clinical scenario.

Synthesis of case reports/series

A single patient case report does not allow the estimation of an effect size and would only provide descriptive or narrative results. Case series of more than one patient may allow narrative or quantitative synthesis.

Narrative synthesis

A systematic review of the cases with the rare syndrome of lipodystrophy was able to suggest core and supportive clinical features and narratively summarised data on available treatment approaches.17 Another systematic review of 172 cases of the infrequently encountered glycogenic hepatopathy was able to characterise for the first time patterns of liver enzymes and hepatic injury in this disease.18

Quantitative synthesis

Quantitative analysis of non-comparative series does not produce relative association measures such as ORs or relative risks but can provide estimates of prevalence or event rates in the form of a proportion (with associated precision). Proportions can be pooled using fixed or random effects models by means of the various available meta-analysis software. For example, a meta-analysis of case series of patients presenting with aortic transection showed that mortality was significantly lower in patients who underwent endovascular repair, followed by open repair and non-operative management (9%, 19% and 46%, respectively, P<0.01).19

A common challenge, however, occurs when proportions are too large or too small (close to 0 or to 1). In this situation, the variance of the proportion becomes very small leading to an inappropriately large weight in meta-analysis. One way to overcome this challenge is to transform prevalence to a variable that is not constrained to the 0–1 range and has approximately normal distribution, conduct the meta-analysis and then transform the estimate back to a proportion.20 This is done using logit transformation or using the Freeman–Tukey double arc sine transformation,21 with the latter being often preferred.22

Another type of quantitative analysis that may be utilised is meta-regression. A meta-analysis of 47 published cases of hypocalcaemia and cardiac dysfunction used univariate linear regression analysis to demonstrate that both QT interval and left ventricular ejection fraction were significantly correlated with corrected total serum calcium level.23 Meta-regression, which is a regression

| Table 1 | Tool for evaluating the methodological quality of case reports and case series |
|------|-------------------------------------|
| Domains | Leading explanatory questions |
| Selection | 1. Does the patient(s) represent(s) the whole experience of the investigator (centre) or is the selection method unclear to the extent that other patients with similar presentation may not have been reported? |
| Ascertainment | 2. Was the exposure adequately ascertained? |
| 3. Was the outcome adequately ascertained? |
| Causality | 4. Were other alternative causes that may explain the observation ruled out? |
| 5. Was there a challenge/rechallenge phenomenon? |
| 6. Was there a dose—response effect? |
| 7. Was follow-up long enough for outcomes to occur? |
| Reporting | 8. Is the case(s) described with sufficient details to allow other investigators to replicate the research or to allow practitioners make inferences related to their own practice? |

Questions 4, 5 and 6 are mostly relevant to cases of adverse drug events.
in which the unit of analysis is a study, not a patient, can also be used to synthesise case series and control for study-level confounders. A meta-regression analysis of uncontrolled series of patients with uveal melanoma treated with proton beam therapy has shown that this treatment was associated with better outcomes than brachytherapy.23 It is very important, however, to recognise that meta-regression results can be severely affected by ecological bias.

From evidence to decision
Several authors have described various important reasons to publish case reports/series (table 2).7 24 25

| Roles                                      | Examples                                                                 |
|--------------------------------------------|--------------------------------------------------------------------------|
| Describe a new phenotype or genotype of disease | The first case report of sickle cell disease.1                              |
| Describe a new pathogen (microbe, virus or environmental exposure) | Discovery of AIDS was an observation of a patient with immunodeficiency-related diseases who otherwise had no reason to be immunodeficient.26 |
| Describe unknown adverse effect of an existing drug | Reye syndrome and aspirin in children.29 Thalidomide and malformation of the limbs in pregnant women.26 |
| Describe a novel treatment for a known condition | Colchicine for the treatment of familial Mediterranean fever.21 |
| Elucidate mechanisms of disease            | Functional imaging of the brain during auditory hallucinations.38         |
| To remind or educate                       | Case presentations in clinicopathological conferences for postgraduate education. |

| Quality improvement                        | “Lesson of the week” published in the British Medical Journal (do not make the same mistake as I did). |

Discussion
Guideline developers and decision-makers often struggle when dealing with case reports/case series. On occasions, they ignore such evidence and focus the scope of guidelines on areas with higher quality evidence. Sometimes they label recommendations based on case reports as expert opinion.32 We propose an approach to evaluate the methodological quality of case reports/series based on the domains of selection, ascertainment, causality and reporting and provide signalling questions to aid evidence-based practitioners and systematic reviewers in their assessment. We suggest the incorporation of case reports/series in decision-making based on the GRADE approach when no other higher level of evidence is available.

In this guide, we have made the case for publishing case reports/series and proposed synthesis of their results in systematic reviews to facilitate using this evidence in decision-making. We have proposed a tool that can be used to evaluate the methodological quality in systematic reviews that examine case reports and case series.

Contributors MHM drafted the paper and all coauthors critically revised the manuscript. All the authors contributed to conceive the idea and approved the final submitted version.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

References
1. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anaemia. Arch Intern Med 1910;VI:517.
2. Meyer H, Lundberg G. Landmark articles in medicine. Chicago: American Medical Association, 1985.
18. Murad MH, Rizvi AZ, Malgor R, et al. Comparative effectiveness of the treatments for thoracic aortic transection [corrected]. J Vasc Surg 2011;53:193–9.
19. Barendregt JJ, Doi SA, Lee YY, et al. Meta-analysis of prevalence. J Epidemiol Community Health 2013;67:974–8.
20. Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat 1950;21:607–11.
21. Newman DB, Fidahussein SS, Kashiwagi DT, et al. Reversible cardiac dysfunction associated with hypocalcemia: a systematic review and meta-analysis of individual patient data. Heart Fail Rev 2014;19:199–205.
22. Wang Z, Nabhan M, Schild SE, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2013;86:18–26.
23. Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med 2001;134:330–4.
24. Aronson JK. Anecdotes as evidence. BMJ 2001;323:1346.
25. Murad MH, Asl运送, Alsawas M, et al. New evidence pyramid. Evid Based Med 2016;21:125–7.
26. Murad MH. Clinical practice guidelines: a primer on development and dissemination. Mayo Clin Proc 2017;92:423–33.
27. Lee WA, Matsumura JS, Mitchell RS, et al. Endovascular repair of traumatic thoracic aortic injury: clinical practice guidelines of the Society for Vascular Surgery. J Vasc Surg 2011;53:187–92.
28. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:346–9.
29. Brito JP, Doney JP, Murad MH, et al. The Endocrine Society guidelines: when the confidence cart goes before the evidence horse. J Clin Endocrinol Metab 2011;96:5246–52.
30. Krzlj V, Petri NM, Mestrovic J, et al. Purpura fulminans successfully treated with hyperbaric oxygen—a report of 2 cases. Pediatr Emerg Care 2005;21:31–4.
31. Ponce OJ, Alvarez-Villalobos N, Shah R, et al. What does expert opinion in guidelines mean? A meta-epidemiological study. Evid Based Med 2017;22:164–9.
32. Bazerbachi F, Conboy EE, Mounajed T, et al. Cryptogenic cirrhosis and sitosterolemia: a treatable disease if identified but fatal if missed. Ann Hepatol 2017;16.
33. Gottlieb MS. Discovering AIDS. Epidemiol 1998;9:365–6.
34. Reeves RD, Morgan G, Baral J. Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood. Lancet 1963:2:749–52.
35. Coodin FJ, Uchida IA, Murphy CH. Phosomelia: report of three cases. Can Med Assoc J 1962;87:735–9.
36. Goldfinger SE. Collchicine for familial Mediterranean fever. N Engl J Med 1972:287:1302.
37. Lennox BR, Park SB, Jones PB, et al. Spatial and temporal mapping of neural activity associated with auditory hallucinations. Lancet 1999;353:644.